

Martin Wagenmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7053355/publications.pdf>

Version: 2024-02-01

104
papers

4,332
citations

117625

34
h-index

123424

61
g-index

140
all docs

140
docs citations

140
times ranked

4254
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating treatment Responses of dupilumab versus omalizumab in Type 2 patients: the EVEREST Trial. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, AB49.	2.9	1
2	Allergen immunotherapy during the COVID-19 pandemic – A survey of the German Society for Allergy and Clinical Immunology. <i>Clinical and Translational Allergy</i> , 2022, 12, e12134.	3.2	6
3	Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 160-168.	1.0	15
4	Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 120-134.	4.4	4
5	Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design. <i>American Journal of Rhinology and Allergy</i> , 2022, 36, 788-795.	2.0	9
6	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
7	EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 29-36.	2.9	178
8	Biologics for atopic diseases: Indication, side effect management, and new developments. <i>Allergologie Select</i> , 2021, 5, 1-25.	3.1	13
9	Schwere allergische Reaktionen auf die Covid-19-Impfung – Stellungnahme und praktische Konsequenzen. <i>Allergologie</i> , 2021, 44, 7-8.	0.1	0
10	COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). <i>Allergologie Select</i> , 2021, 5, 251-259.	3.1	9
11	Update of the S2k guideline on the management of IgE-mediated food allergies. <i>Allergologie Select</i> , 2021, 5, 195-243.	3.1	42
12	COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologics) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology. <i>Allergologie Select</i> , 2021, 5, 140-147.	3.1	28
13	Severe allergic reactions to the COVID-19 vaccine – statement and practical consequences. <i>Allergologie Select</i> , 2021, 5, 26-28.	3.1	33
14	Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. <i>Allergo Journal International</i> , 2021, 30, 51-55.	2.0	55
15	Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1087-1101.	2.8	48
16	Health-Related Quality of Life Impairment Among Patients With Severe Chronic Rhinosinusitis With Nasal Polyps in the SINUS-24 Trial. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, AB133.	2.9	0
17	CD44v6-targeted CAR T-cells specifically eliminate CD44 isoform 6 expressing head/neck squamous cell carcinoma cells. <i>Oral Oncology</i> , 2021, 116, 105259.	1.5	22
18	COVID-19-Impfungen von allergischen Patienten im zeitlichen Zusammenhang mit einer Allergen-Immuntherapie (AIT) – Ein Positionspapier des Ärztverbandes Deutscher Allergologen (AeDA) und der Deutschen Gesellschaft für Allergologie und Klin. Allergologie, 2021, 44, 339-348.	0.1	0

#	ARTICLE	IF	CITATIONS
19	ARIA&EAACI care pathways for allergen immunotherapy in respiratory allergy. Clinical and Translational Allergy, 2021, 11, e12014.	3.2	24
20	Update Leitlinie zum Management IgE-vermittelter Nahrungsmittelallergien &S2k-Leitlinie der DGAKI. Allergologie, 2021, 44, 488-541.	0.1	8
21	Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine, 2021, 9, 1141-1153.	10.7	263
22	MultimorbiditÄ bei allergischer Rhinitis. Allergologie, 2021, 44, 22-30.	0.1	0
23	Biologika bei atopischen Erkrankungen: Indikationsstellung, Nebenwirkungsmanagement und neue Entwicklungen. Allergologie, 2021, 44, 54-80.	0.1	0
24	Precision medicine reaching out to the patients in allergology &S2a German-Japanese workshop report. Allergologie Select, 2021, 5, 162-179.	3.1	1
25	Wir stellen uns vor: Sektion HNO der DGAKI. Allergologie, 2021, 44, 811-812.	0.1	0
26	A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR TÄcells. Molecular Therapy - Oncolytics, 2021, 23, 534-546.	4.4	9
27	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clinical and Translational Allergy, 2020, 10, 1.	3.2	110
28	Is allergy immunotherapy with birch sufficient to treat patients allergic to pollen of tree species of the birch homologous group?. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1327-1336.	5.7	13
29	Effect of the tongue-in-groove technique on the smile form. Rhinology, 2020, 58, 626-628.	1.3	10
30	Real&S2a life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2867-2878.	5.7	45
31	Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement. World Allergy Organization Journal, 2020, 13, 100124.	3.5	25
32	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. Allergologie Select, 2020, 4, 44-52.	3.1	23
33	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. Allergologie Select, 2020, 4, 53-68.	3.1	38
34	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	3.2	87
35	Food allergy knowledge, attitudes and their determinants among restaurant staff: A cross-sectional study. PLoS ONE, 2019, 14, e0214625.	2.5	22
36	Randomized immunotherapy trial in dual&S2a allergic patients using &S2a active allergen placebo&S2a as control. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1480-1489.	5.7	10

#	ARTICLE	IF	CITATIONS
37	<sc>ARIA</sc> pharmacy 2018 – Allergic rhinitis care pathways for community pharmacy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52
38	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	2.9	103
39	Activin-A Is a Pro-Inflammatory Regulator in Type-2-Driven Upper Airway Disease. International Archives of Allergy and Immunology, 2018, 176, 15-25.	2.1	5
40	EAACI Position paper on the standardization of nasal allergen challenges. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1597-1608.	5.7	161
41	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<sc>MACVIA</sc> – <sc>ARIA</sc>) – <sc>EIP</sc> on <sc>AHA</sc> Twinning Reference Site (<sc>GARD</sc> research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	5.7	54
42	Electronic Clinical Decision Support System for allergic rhinitis management: MASK – CDSS. Clinical and Experimental Allergy, 2018, 48, 1640-1653.	2.9	61
43	Visuelle Analogskalen (VAS) als Messinstrumente zur Dokumentation der Symptomatik und Therapiekontrolle einer allergischen Rhinitis in der Routineversorgung. Allergologie, 2018, 41, 364-374.	0.1	5
44	Mutational and Functional Analysis of FANCB as a Candidate Gene for Sporadic Head and Neck Squamous Cell Carcinomas. Anticancer Research, 2018, 38, 1317-1325.	1.1	5
45	Unverträglichkeitsreaktionen und Allergien bei implantierbaren Hörsystemen. Allergologie, 2018, 41, 140-144.	0.1	0
46	Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care. Allergo Journal International, 2017, 26, 16-24.	2.0	292
47	Biomarkers in Allergic Airway Disease: Simply Complex. Orl, 2017, 79, 72-77.	1.1	6
48	Radiomics in Head and Neck Cancer: Extracting Valuable Information from Data beyond Recognition. Orl, 2017, 79, 65-71.	1.1	11
49	Endotypes in Chronic Rhinosinusitis: Biomarkers Based on a Mechanistic Insight for Targeted Treatment?. Orl, 2017, 79, 78-84.	1.1	6
50	Validation of the <sc>MASK</sc> rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clinical and Experimental Allergy, 2017, 47, 1526-1533.	2.9	75
51	Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies. Gene Therapy, 2016, 23, 615-626.	4.5	30
52	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29.	3.2	47
53	Cytokine Patterns and Endotypes in Acute and Chronic Rhinosinusitis. Current Allergy and Asthma Reports, 2016, 16, 3.	5.3	29
54	Leitlinie zum Management IgE-vermittelter Nahrungsmittelallergien. Allergologie, 2016, 39, 302-344.	0.1	0

#	ARTICLE	IF	CITATIONS
55	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	5.7	160
56	An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial. <i>Clinical and Translational Allergy</i> , 2015, 6, 4.	3.2	16
57	Taking a Fresh Look at the Skull Base in Otorhinolaryngology With Web-Based Simulation. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 154.	2.2	7
58	Challenges in Histologic Diagnosis of Nonchordomatous Lesions of the Clivus. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 745.	2.2	2
59	AluY-mediated germline deletion, duplication and somatic stem cell reversion in <i>UBE2T</i> defines a new subtype of Fanconi anemia. <i>Human Molecular Genetics</i> , 2015, 24, 5093-5108.	2.9	62
60	Guidelines on the management of IgE-mediated food allergies. <i>Allergo Journal International</i> , 2015, 24, 256-293.	2.0	129
61	Release Kinetics Of Soluble ST2 and Proinflammatory Cytokines In Allergic Rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB143.	2.9	0
62	RAD51C – A new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC). <i>Oral Oncology</i> , 2014, 50, 196-199.	1.5	27
63	MP29-02 (Dymista®) – Eine neue Behandlungsoption für die allergische Rhinitis. <i>Allergologie</i> , 2014, 37, 55-68.	0.1	1
64	Ein Comeback für die Capsaicin- Therapie bei nicht-allergischer Rhinitis?. <i>Allergologie</i> , 2014, 37, 476-478.	0.1	0
65	Vascularised local and free flaps in anterior skull base reconstruction. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 899-907.	1.6	31
66	Nasal levels of soluble <i>IL-33</i> and <i>ST2</i> in allergic rhinitis: inverse correlation trends with disease severity. <i>Clinical and Experimental Allergy</i> , 2013, 43, 1134-1143.	2.9	29
67	Comparison of the Nasal Release of IL-4, IL-10, IL-17, CCL13/MCP-4, and CCL26/eotaxin-3 in Allergic Rhinitis during Season and after Allergen Challenge. <i>American Journal of Rhinology and Allergy</i> , 2013, 27, 266-272.	2.0	52
68	Squamous Cell Carcinomas of the Head and Neck in Fanconi Anemia: Risk, Prevention, Therapy, and the Need for Guidelines. <i>Klinische Padiatrie</i> , 2012, 224, 132-138.	0.6	35
69	The release of <i>IL-31</i> and <i>IL-13</i> after nasal allergen challenge and their relation to nasal symptoms. <i>Clinical and Translational Allergy</i> , 2012, 2, 13.	3.2	26
70	Nonallergic Rhinitis-Identifying Gaps in Research. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, AB254-AB254.	2.9	0
71	Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1515-1521.e6.	2.9	26
72	Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis.. <i>Rhinology</i> , 2011, 49, 272-280.	1.3	15

#	ARTICLE	IF	CITATIONS
73	Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. <i>Rhinology</i> , 2011, 49, 272-280.	1.3	26
74	The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN). <i>Journal of Negative Results in BioMedicine</i> , 2010, 9, 10.	1.4	2
75	Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. <i>Auris Nasus Larynx</i> , 2010, 37, 322-328.	1.2	70
76	Analysis of TLR2, TLR4, TLR5, and TLR9 Polymorphisms in Chronic Rhinosinusitis (CRS). <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, S145-S145.	2.9	0
77	Surgical management of retropharyngeal abscesses. <i>Acta Oto-Laryngologica</i> , 2009, 129, 1274-1279.	0.9	24
78	Nasal Provocation Testing. , 2009, , 1281-1294.		2
79	An intronic alteration of the fibroblast growth factor 10 gene causing ALSG-(aplasia of lacrimal and) Tj ETQq1 1 0.784314 rgBT /Overlock 14	2.1	14
80	Th2-Cytokines Dominate the Allergic Inflammation after Nasal Allergen Provocation while Chronic Natural Allergen Exposure also induces Th1-Cytokines. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, S276-S276.	2.9	0
81	Regulatory Cytokines In Chronic Rhinosinusitis With And Without Nasal Polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, S243.	2.9	0
82	Squamous Cell Cancer and Human Papillomavirus Infection in Oral Lichen Planus: Case Report and Literature Review. <i>Dermatologic Surgery</i> , 2007, 33, 756-760.	0.8	9
83	The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 1132-1138.	5.7	54
84	Der ELISPOT-Assay, eine hochsensitive Methode zur Untersuchung der Zytokinproduktion der Nasenschleimhaut. <i>Allergologie</i> , 2005, 28, 401-411.	0.1	1
85	Cytokine production in the sinus mucosa is correlated to clinical parameters of chronic sinusitis before and after sinus surgery. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S84-S84.	2.9	0
86	DurchfÅ¼hrung des nasalen Provokationstests bei Erkrankungen der oberen Atemwege â€œ Positionspapier der Deutschen Gesellschaft fÅ¼r Allergologie und Klinische Immunologie (Sektion) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	0
87	Elevated levels of myeloperoxidase, pro-inflammatory cytokines and chemokines in naturally acquired upper respiratory tract infections. <i>European Archives of Oto-Rhino-Laryngology</i> , 2001, 258, 406-412.	1.6	29
88	Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2001, 37, 50-56.	1.5	25
89	622 Increased production of type-2 and type1 cytokines in nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S210.	2.9	7
90	The role of cytokines in infectious sinusitis and nasal polyposis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1998, 53, 2-13.	5.7	140

#	ARTICLE	IF	CITATIONS
91	Cytokines and Adhesion Molecules in Allergic Rhinitis. American Journal of Rhinology & Allergy, 1998, 12, 3-8.	2.2	36
92	Bilateral increases in histamine after unilateral nasal allergen challenge.. American Journal of Respiratory and Critical Care Medicine, 1997, 155, 426-431.	5.6	24
93	Specific Immunotherapy Suppresses IL-1 β and IL-8 Levels in Nasal Secretions: A Possible Explanation for the Inhibition of Inflammatory Cell Migration. Oto-rhino-laryngologia Nova, 1997, 7, 31-39.	0.0	4
94	IL-5 synthesis is upregulated in human nasal polyp tissue1. Journal of Allergy and Clinical Immunology, 1997, 99, 837-842.	2.9	317
95	Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D ₂ . Clinical and Experimental Allergy, 1996, 26, 371-378.	2.9	27
96	Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D ₂ . Clinical and Experimental Allergy, 1996, 26, 371-8.	2.9	7
97	Proinflammatory Cytokines: Measurement in Nasal Secretion and Induction of Adhesion Receptor Expression. International Archives of Allergy and Immunology, 1995, 107, 106-108.	2.1	58
98	Elevated levels of interleukins IL-1 β , IL-6 and IL-8 in naturally acquired viral rhinitis. European Archives of Oto-Rhino-Laryngology, 1995, 252, S61-S63.	1.6	52
99	Onset and duration of inhibition of ipratropium bromide nasal spray on methacholine-induced nasal secretions. Clinical and Experimental Allergy, 1994, 24, 288-290.	2.9	21
100	The effect of terfenadine on unilateral nasal challenge with allergen. Journal of Allergy and Clinical Immunology, 1994, 93, 594-605.	2.9	38
101	Effect of Terfenadine on Nasal Provocation. International Archives of Allergy and Immunology, 1993, 101, 311-317.	2.1	9
102	Comparison of the secretory response of the nasal mucosa to methacholine and histamine. Journal of Applied Physiology, 1993, 74, 2661-2671.	2.5	90
103	Anatomic and physiologic considerations in sinusitis. Journal of Allergy and Clinical Immunology, 1992, 90, 419-423.	2.9	64
104	Complications of sinusitis. Journal of Allergy and Clinical Immunology, 1992, 90, 552-554.	2.9	54